Evidence map›Paper›PMID 39359828›Full record

ReviewAnnals of medicine and surgery (2012)2024

Efficacy and safety of mavacamten for the treatment of hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials.

Naiela Ennaji Almansouri, Syed Ali Uzair Nadeem Bukhari, Muhammad Hassan Qureshi, Muhammad Idrees, Chaudhry Zaid Riaz, Arshman Rauf Asghar, Ayesha Habib, Jibran Ikram, Muhammad Ehsan, Wajeeh Ur Rehman and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of medicine and surgery (2012), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Naiela Ennaji AlmansouriDepartment of Medicine, University of Tripoli, Tripoli, Libya.
Syed Ali Uzair Nadeem BukhariDepartment of Medicine, FMH College of Medicine and Dentistry.
Muhammad Hassan QureshiDepartment of Medicine, CMH Lahore Medical College.
Muhammad IdreesDepartment of Medicine, Multan Institute of Kidney Diseases, Multan.
Chaudhry Zaid RiazDepartment of Medicine, Madinah Teaching Hospital.
Arshman Rauf AsgharDepartment of Medicine, CMH Lahore Medical College.
Ayesha HabibDepartment of Medicine, Faisalabad Medical University, Faisalabad.
Jibran IkramDepartment of Medicine, Lifecare Hospital & Research Institute, Peshawar, Pakistan.
Muhammad EhsanDepartment of Medicine, King Edward Medical University, Lahore.ORCID https://orcid.org/0000-0002-6021-2342
Wajeeh Ur RehmanDepartment of Medicine, United Health Services, Johnson City, New York.
Huzaifa Ahmad CheemaDepartment of Medicine, King Edward Medical University, Lahore.
Muhammad AyyanDepartment of Medicine, King Edward Medical University, Lahore.
Kamal KandelDepartment of Medicine, Kathmandu University, Nepal.ORCID https://orcid.org/0000-0002-2413-9774
Sana IqbalDMC Sinai Grace Hospital, Detroit, MI.
Ahmed PashaHeart and Vascular Institute, United Health Services, Johnson City, NY.
Keyoor PatelHeart and Vascular Institute, United Health Services, Johnson City, NY.
Mouhammad Amr SabouniCardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy and safety profile of mavacamten, a cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) is not well-established, prompting the need for an updated meta-analysis. The authors conducted an extensive search across multiple electronic databases, including Embase, MEDLINE (via Pubmed), and CENTRAL, to identify randomized controlled trials (RCTs) assessing the efficacy and safety of mavacamten in HCM. Review Manager 5.4 (Revman) was employed to pool risk ratios (RR) and mean differences (MD). Our literature search yielded 4 RCTs with a total of 503 patients. Mavacamten was found to be associated with higher rates of greater than or equal to 1 New York Heart Association (NYHA) class improvement (RR 2.20, 95% CI: 1.48-3.28; I

Indexed as

HOCMhypertrophic cardiomyopathyhypertrophic obstructive cardiomyopathymavacamten

Identifiers

PMID39359828
PMCPMC11444588

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.